Berkshire Asset Management LLC Immuno Gen, Inc. Transaction History

Berkshire Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $33,934 - $62,052	-10,773 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $685 - $1,204	-161 Reduced 1.47%	10,773 $51,000
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $2,954 - $4,665	-622 Reduced 5.38%	10,934 $81,000
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $818 - $1,074	-163 Reduced 1.39%	11,556 $66,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $943 - $1,401	163 Added 1.41%	11,719 $77,000
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $5,466 - $8,855	-841 Reduced 6.78%	11,556 $94,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $45,868 - $94,961	12,397 New	12,397 $80,000
Q2 2020 Aug 12, 2020	SELL	$3.32 - $5.34 $39,381 - $63,343	-11,862 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$2.12 - $6.8 $25,147 - $80,661	11,862 New	11,862 $40,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Berkshire Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Berkshire Asset Management LLC with notifications on news.